Table 1 Subject characteristics
Characteristics | All patients (n = 85) | IgE analysis (n = 80) | AEC analysis (n = 54) |
|---|---|---|---|
Gender | |||
Male: n (%) | 41 (48.2%) | 38 (47.5%) | 27 (50.0%) |
Female: n (%) | 44 (51.8%) | 42 (52.5%) | 27 (50.0%) |
Age | |||
Between 18 and 30 years | 38 (44.7%) | 37 (46.3%) | 23 (42.6%) |
Between 30 and 50 years | 36 (42.4%) | 33 (41.2%) | 24 (44.4%) |
Above 50 years | 11 (12.9%) | 10 (12.5%) | 7 (13.0%) |
Mean (SD) | 34.2 (10.7) | 33.7 (10.3) | 34.7 (11.0) |
Median (IQR) | 31.8 (12.8) | 30.9 (13.0) | 32.6 (13.2) |
CFTR Mutation Information | |||
delF508 Homozygous | 49 (57.7%) | 48 (60.0%) | 32 (59.3%) |
delF508 Heterozygous | 34 (40.0%) | 30 (37.5%) | 22 (40.7%) |
Other Mutation | 2 (2.4%) | 2 (2.5%) | 0 (0.0%) |
Initial Disease Severity | |||
Normal (ppFEV1 > 90%) | 23 (27.1%) | 22 (27.5%) | 13 (24.1%) |
Mild (70% < ppFEV1 ≤ 90%), | 26 (30.6%) | 25 (31.2%) | 19 (35.2%) |
Moderate (40% < ppFEV1 ≤ 70%) | 25 (29.4%) | 23 (28.7%) | 17 (31.5%) |
Severe (ppFEV1 ≤ 40%) | 10 (11.8%) | 10 (12.5%) | 4 (7.4%) |
Not Available | 1(1.2%) | 0 (0.0%) | 1 (1.9%) |
Pre-ETI Inhaled Steroids | |||
Yes | 51 (60.0%) | 49 (61.3%) | 30 (55.6%) |
No | 33 (38.8%) | 30 (37.5%) | 24 (44.4%) |
Not Available | 1 (1.2%) | 1 (1.3%) | 0 (0.0%) |
Colonization | |||
MRSA | 25 (29.4%) | 21 (26.3%) | 17 (31.5%) |
Pseudomonas | 50 (58.8%) | 48 (60.0%) | 29 (53.7%) |
Other Bacteria | 32 (37.6%) | 31 (38.8%) | 21 (38.9%) |
Fungus | 36 (42.4%) | 36 (45.0%) | 25 (46.3%) |
Not Available | 1 (1.2%) | 1 (1.3%) | 0 (0.0%) |